population pharmacokinetic model (NONMEM v7.2) . Pharmacokinetic parameters derived from steady-state simulations based on the final model were also evaluated.
Results: C1-INH functional activity following C1-INH (SC) administration was
described by a linear one-compartment model with first-order absorption and elimination, with inter-individual variability in all parameters tested. The mean population bioavailability of C1-INH (SC), and pharmacokinetic parameters for clearance (CL), volume of distribution, and absorption rate were estimated to be~43%, 1.03 mL/ hour/kg, 0.05 L/kg and 0.0146 hour −1 , respectively. The effect of bodyweight on CL of C1-INH functional activity was included in the final model, estimated to be 0.74.
Steady-state simulations of C1-INH functional activity vs time profiles in 1000 virtual HAE patients revealed higher minimum functional activity (C trough ) levels after twice-weekly dosing with 40 IU/kg (~40%) and 60 IU/kg (~48%) compared with 1000 IU IV (~30%). Based on the population pharmacokinetic model, the median time to peak concentration was~59 hours and the median apparent plasma half-life was~69 hours.
Conclusions and Clinical Relevance:
Twice-weekly bodyweight-adjusted dosing of
C1-INH (SC) exhibits linear pharmacokinetics and dose-dependent increases in
C trough levels at each dosing interval. In this analysis, SC dosing led to maintenance of higher C trough levels than IV dosing.
K E Y W O R D S
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| INTRODUCTION
Hereditary angioedema (HAE) is a rare autosomal dominant disease characterized by clinical symptoms including angioedema without urticaria or pruritus, generally affecting the subcutaneous (SC) tissues of the trunk, limbs or face, or the submucosal tissues of the respiratory, gastrointestinal or genitourinary tracts. [1] [2] [3] [4] Without treatment, acute attacks can be life-threatening and may require hospitalization; moreover, many patients experience impaired quality of life. 1, 2, [5] [6] [7] Management of HAE involves the treatment of acute attacks, as well as short-and long-term prophylaxis in many patients.
Mutations on the SERPING1 gene encoding the C1-esterase inhibitor (C1-INH) are responsible for the 2 most common types of HAE, type I (hereditary angioedema with deficient C1-INH; 85% of patients) and type II (hereditary angioedema with dysfunctional C1-_INH; 15% of patients). 1, 5, 8, 9 In healthy individuals, C1-INH acts on the plasma kallikrein-bradykinin system to prevent excess generation of bradykinin and thus spontaneous activation of inflammatory reactions. 1, 5, 10 An absence in or dysfunction of C1-INH is the primary abnormality in patients with HAE, and a plasma-derived C1-INH twice-weekly intravenous (IV) injection provides a safe and generally effective treatment to reduce attacks of angioedema. 1, 5, 11, 12 Consensus guidelines recommend C1-INH prophylaxis in patients who do not achieve sufficient benefit from on-demand treatment. 
| Study 1 (Healthy volunteers; NCT01760343)
This was a randomized, double-blind, single-centre, cross-over phase 
| Study 2 (Patients with HAE; NCT01576523)
This was an open-label, dose-ranging, cross-over phase II study to 
| Study 3 (Patients with HAE; NCT01912456)
This was a double-blind, randomized, placebo-controlled, cross-over study to evaluate the clinical efficacy and safety of C1-INH (SC) (COMPACT phase III study). Ninety patients aged ≥ 12 years with a clinical diagnosis of HAE type I or II were randomly assigned 
| PK measurements
Plasma C1-INH functional activity was assessed by a validated chromogenic assay (Berichrom C1-inhibitor, Siemens Eschborn, Germany;
reference range: 70%-130% of norm). All measurements were performed at a central laboratory (CSL Behring GmbH). Plasma C1-INH functional activity and C1-INH antigen were assessed in all 3 clinical studies.
| PK analysis

| Model development
The PK population included subjects who received C1-INH either as an IV or SC dose, and contributed at least 1 measurable PK concen- | 1327
| Model evaluation (visual predictive check)
Model evaluation was conducted using the final model to simulate 1000 datasets based on bodyweight (the only covariate found to influence clearance), sampling times and the dosing histories contained in the dataset. The model was subjected to a nonparametric bootstrap analysis, generating 1000 datasets through random sampling with replacement from the original data, using the individual as the sampling unit.
| Simulations
Based on the distribution of individual weights in a HAE population, 3 | RESULTS
| PK population
A total of 124 subjects (108 with HAE and 16 healthy volunteers)
were included in the PK analysis dataset, which comprised of a total of 2103 C1-INH functional activity observations. Population demographics are summarized in Table 1 . (Table S1) ,
where the mean population F of C1-INH (SC) was fixed to the value previously described. 17 The observed C1-INH functional activity was modelled as the sum of the patient's endogenous C1-INH plus administered (exogenous) C1-INH.
As expected, the baseline C1-INH functional activity was unambiguously different between healthy subjects and those with HAE, therefore separate baseline parameters were estimated for each population.
| Full model
The relationships between the model parameters, and covariates of clinical interest (gender, age and bodyweight) were examined visually then added simultaneously to form a full model. The small number of non-Caucasian subjects included (<10% of the population) meant that race could not be included as a covariate for the analysis. A summary of the final PK parameter estimates is provided in Table 2 .
The only statistically significant covariate effect was that of bodyweight on CL, which was accounted for in the final model by including bodyweight as a covariate on CL ( Table 2 ).
The final model can be described by the following equation: 
| Final model evaluation
The observed concentrations for healthy subjects and patients at the 
| Simulations of C1-INH (SC) vs C1-INH (IV)
A summary of the model-predicted geometric mean maximum plasma C1-INH functional activity levels (C max ), minimum functional activity levels (C trough ), median time to peak concentration (T max ) , half-life and area under the activity-time curve from pre-dose to the end of the dosing interval at steady state (AUC 0-τ ) are presented in Table 3 .
Based on the final model, mean C max was 48.7% for 40 IU/kg and 60.7% for 60 IU/kg, and 56.3% and 104% for 1000 IU and 2500 IU 
C1-INH (IV). Mean
25,26
The current analysis is a comprehensive pooled population PK analysis conducted using data from 3 clinical studies, and is thus a Inter-individual or inter-occasion variability Performing a pooled population PK analysis enabled the inclusion of data from all studies, including sparse data, from the phase III study to characterize the PK of C1-INH (SC). A population PK analysis of the phase II study provided a good description of C1-INH functional activity and revealed a significant effect of bodyweight on CL. 17 The use of population modelling throughout the process assisted in designing studies with optimal samples for PK and to make comparisons of various dosing scenarios without conducting the clinical trials.
In conclusion, our analysis demonstrates that in patients with HAE, long-term prophylaxis with bodyweight-based SC dosing of C1-INH provides consistent and higher trough levels of C1-INH functional activity at the next dosing interval compared with IV route of administration at the currently recommended dosing (1000 IU and 2500 IU twice-weekly).
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